An overview of GLP-1 science, GLP-1 medicines, key trials and emerging innovation
Daniel Drucker is a Senior Scientist, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital and a Professor of Medicine, at the University of Toronto. His laboratory studies the molecular biology and physiology and translational science of the glucagon-like peptides, These studies have supported the development of multiple different classes of medicine for the treatment of metabolic disorders.